Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

RFA for Small HCC With No-touch Technique Using Octopus Electrode

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02832882
Recruitment Status : Unknown
Verified July 2016 by Jeong Min Lee, Seoul National University Hospital.
Recruitment status was:  Not yet recruiting
First Posted : July 14, 2016
Last Update Posted : July 14, 2016
Sponsor:
Information provided by (Responsible Party):
Jeong Min Lee, Seoul National University Hospital

Brief Summary:
In this study, the investigators are going to prospectively compare the clinical outcomes (technical success rate, 12 month local tumor progression rate, complication rate, tumor seeding rate) of Radiofrequency ablation (RFA) with octopus electrode and no-touch technique for Hepatocellular carcinoma (HCC) to those of RFA with conventional tumor puncture method with the same device.

Condition or disease Intervention/treatment Phase
Carcinoma, Hepatocellular Procedure: No-touch RFA Procedure: Conventional tumor puncture RFA Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Radiofrequency Ablation for Small Hepatocellular Carcinoma Using Octopus Electrode and No-touch Technique: Preliminary Study
Study Start Date : July 2016
Estimated Primary Completion Date : January 2018
Estimated Study Completion Date : January 2018

Arm Intervention/treatment
Experimental: No-touch RFA arm
No-touch RFA arm indicates RFA procedure using Octopus electrode and no touch technique.
Procedure: No-touch RFA
No-touch RFA indicates RFA without tumor puncture. In this study, no-touch RFA is performed using Octopus electrodes.

Active Comparator: Conventional tumor puncture RFA arm
Conventional tumor puncture RFA arm indicates RFA procedure using Octopus electrode and conventional tumor puncture technique.
Procedure: Conventional tumor puncture RFA
Conventional tumor puncture RFA indicates routine procedure of RFA in our institution. In this study, RFA procedure is performed using Octopus electrodes.




Primary Outcome Measures :
  1. 12 month local tumor progression (LTP) rate [ Time Frame: 12 month after RFA ]

Secondary Outcome Measures :
  1. tumor seeding rate [ Time Frame: 12 months after RFA ]
    incidence of tract seeding after RFA.

  2. Complication rate related with RFA [ Time Frame: 1 month ]
    RFA-related complication rate such as death, abscess, bleeding..etc.

  3. Technical success rate [ Time Frame: 1 months ]
    presence or absence of residual lesion on follow-up imaging


Other Outcome Measures:
  1. Ablation time [ Time Frame: 3 days after RFA ]
    ablation time for tumor ablation

  2. Intrahepatic distant mets [ Time Frame: 12 months after RFA ]
    incidence of intrahepatic distant metastasis after RFA

  3. Extrahepatic distant mets [ Time Frame: 12 months after RFA ]
    incidence of extrahepatic distant metastasis after RFA

  4. Technical efficacy 1 [ Time Frame: 2 days after RFA ]
    Assessment of ablative margin using score 1-4 (1: residual tumor; 4: equal to or larger than 5mm) in side-by-side comparison of pre-RFA CT/MR and post-RFA CT using visual assessment

  5. Technical efficacy 2 [ Time Frame: 2 days after RFA ]
    Assessment of ablative margin using score 1-4 (1: residual tumor; 4: equal to or larger than 5mm) in side-by-side comparison of pre-RFA CT/MR and post-RFA CT using registration software



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Child-Pugh class A
  • patient with 1cm-2.5cm sized HCC
  • 1 or 2 HCCs
  • being referred for curative purpose of RFA
  • sign informed consent

Exclusion Criteria:

  • maximum tumor diameter greater than 2.5cm
  • Child-Pugh class B or C
  • more than 3 HCC lesions
  • invisible tumor even after US/CT or US/MR fusion
  • presence of vascular tumor thrombosis or extrahepatic metastasis
  • severe coagulopathy (PLT < 50K, PT < 50% of normal range)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02832882


Contacts
Layout table for location contacts
Contact: Hyun Hee Lee, RN 82-2-2072-4177 redlion55@naver.com

Sponsors and Collaborators
Seoul National University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Jeong Min Lee, MD Seoul National University Hospital
Layout table for additonal information
Responsible Party: Jeong Min Lee, Professor, Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT02832882    
Other Study ID Numbers: SNUH-2016-2244
First Posted: July 14, 2016    Key Record Dates
Last Update Posted: July 14, 2016
Last Verified: July 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Jeong Min Lee, Seoul National University Hospital:
HCC
RFA
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases